Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 27,795 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo and sham treatment Clear all
Completed Phase 3 Interventional

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

NCT01018173
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Buena Park, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 24, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders

NCT04725383
View directory record Official record
Conditions
Autism Spectrum Disorder, Repetitive Compulsive Behavior
Interventions
amitriptyline
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
6 Years to 17 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Riluzole in Treatment Resistant Depression

NCT01204918
View directory record Official record
Conditions
Depression
Interventions
Riluzole, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
New Haven, Connecticut • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2020 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

NCT02961218
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
8 Years to 20 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional

A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis

NCT00323518
View directory record Official record
Conditions
Oral Mucositis, Stomatitis
Interventions
velafermin, placebo
Drug
Lead sponsor
CuraGen Corporation
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
33
States / cities
Little Rock, Arkansas • Berkley, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CollaRx® Bupivacaine Implant in Men After Open Laparotomy Herniorrhaphy

NCT01220024
View directory record Official record
Conditions
Herniorrhaphy, Postoperative Pain, Inguinal Hernia
Interventions
Bupivacaine Collagen Sponge, Placebo collagen Sponge
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotine, Non-Smokers With and Without ADHD, and Genetics Study

NCT01819259
View directory record Official record
Conditions
Non-smoker, ADHD
Interventions
Nicotine nasal spray, Placebo
Drug
Lead sponsor
Scott Kollins, PhD
Other
Eligibility
18 Years to 25 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes

NCT03289923
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Sham TMS + Cognitive therapy, Active TMS + Cognitive therapy
Device
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Ascending Dose in Japanese Patients Bridging Study

NCT05065359
View directory record Official record
Conditions
Healthy
Interventions
Rodatristat Ethyl 300 mg BID, Rodatristat Ethyl 600 mg BID, Placebo
Drug
Lead sponsor
Altavant Sciences GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2022 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00334880
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
48
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis

NCT00265096
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
golimumab, Placebo; golimumab
Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
18
States / cities
Huntsville, Alabama • La Jolla, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

NCT05629962
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19
Interventions
Bemnifosbuvir (BEM), Placebo
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Kingman, Arizona • Prescott, Arizona • Surprise, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2025 · Synced Oct 24, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Results available

Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)

NCT01212588
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
mifepristone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 64 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 24, 2026, 4:13 AM EDT
Terminated Phase 3 Interventional Results available

AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department

NCT04669288
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Months to 60 Months
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers

NCT05626803
View directory record Official record
Conditions
Norovirus Infections
Interventions
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose, Placebo
Drug
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 80 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
3
States / cities
Long Beach, California • Lenexa, Kansas • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Metoprolol to Reduce Perioperative Myocardial Injury

NCT03138603
View directory record Official record
Conditions
Heart Diseases
Interventions
Metoprolol Tartrate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study of LY3372689 Given By Mouth to Healthy Participants

NCT03819270
View directory record Official record
Conditions
Healthy
Interventions
LY3372689, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 24, 2026, 4:13 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide to Slow Biological Aging

NCT07220473
View directory record Official record
Conditions
Aging, LONGEVITY 1
Interventions
Zepbound
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
55 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Results available

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

NCT04375397
View directory record Official record
Conditions
CoronaVirus Induced Disease-2019 (COVID-19)
Interventions
Ibrutinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 24, 2026, 4:13 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Radicle GI HealthTM VNB: A Study Assessing the Impact of Health and Wellness Products on Constipation and Related Health Outcomes

NCT07713810
View directory record Official record
Conditions
Constipation
Interventions
Placebo GI Health Control, Active GI Health Product
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
550 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Chronic Dietary Grape Seed Extract Supplementation on Aortic Stiffness and Hemodynamic Responses to Exercise in Obese Males

NCT04465110
View directory record Official record
Conditions
Obesity Adult Onset
Interventions
Grape Seed Extract
Dietary Supplement
Lead sponsor
California Baptist University
Other
Eligibility
18 Years to 29 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Gilbert, Arizona • Clovis, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

NCT02683746
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Lyophilized albiglutide DCC pen injector, Lyophilized albiglutide DCC pen injector matching placebo, Albiglutide liquid auto-injector, Albiglutide liquid auto-injector matching placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
70
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 24, 2026, 4:13 AM EDT